Discover FDA recommendations for designing clinical trials of gene therapy for neurodegenerative diseases. Learn about study design, patient selection, dose considerations, safety issues, and the role of patient experience data in advancing these transformative therapies.
Introduction to Gene Therapy and Neurodegenerative Diseases
Gene therapy is a revolutionary therapeutic approach that holds the promise of transforming the landscape of medicinal treatment for neurodegenerative conditions that have proved to be most difficult to manage for some time now. Over the past few decades, there has been a growing worldwide prevalence of neurodegenerative disorders, leading researchers and healthcare providers to find ways to treat this global phenomenon. These conditions include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease, each of which presents a tremendous burden on affected persons, caregivers, and health systems.
FDA Recommendations for Clinical Trials of Gene Therapy
Gene therapy is an emerging therapeutic platform, and the FDA has been instrumental in regulating and guiding the clinical development of gene therapy products targeting neurodegenerative diseases. Recognizing the multifaceted nature of these disorders, the FDA has provided some high-level considerations that researchers and sponsors should keep in mind when developing clinical trials to evaluate the safety and effectiveness of gene therapy approaches.
The purpose of this article is to summarize the most relevant recommendations given by the FDA related to clinical studies of gene therapy products for neurodegenerative disorders. With knowledge of these guidelines and a commitment to following them, researchers may better navigate the hurdles associated with translating their therapeutic innovations from the bench to the bedside and ultimately change the paradigm for treating neurodegenerative disease.
Gene therapy (GT) has incredible potential to be a game changer in the treatment of any neurodegenerative disease. While pursuit of this novel therapeutic modality continues, the Food and Drug Administration (FDA) has provided important considerations for the design of clinical trials of GT products to treat neurodegenerative disorders. Through making use of the medical device pivotal, the FDA will expedite clinical developments to facilitate development of safe and potentially effective neurodegenerative medicines which can be transformative for these patients, as highlighted in this article.
Study Design Considerations
Study Design: Because of the unique characteristics of every neurodegenerative disorder, clinical trial design needs to be disorder specific. Innovative trial designs may be possible for well-defined monogenic disorders where the molecular outcome is predictable and there is a large therapeutic effect. For such disorders, traditional randomized, placebo controlled trials may not be required. Instead, consider designs so called add-on designs where subjects receive a treatment that has been shown effective for the condition prior to randomization. It minimizes the exposure of inactive tablets to patients and speeds up the clinical development process.
Nevertheless, in neurodegenerative diseases with uncertain etiology and pathophysiology, randomized, concurrent-controlled trials with adequate masking are still necessary to provide compelling efficacy data. Innovative trial designs such as adaptive designs, enrichment designs, dose-controlled studies, or historical controls can expedite product development and should be considered by sponsors for efficiency; however, early communication with the FDA is encouraged to establish agreement towards these design adaptations.
Study Candidates:
Choosing study subjects for most clinical trials is fundamental to the success of the trial and the generalizability of the findings. Accurate genetic diagnosis is crucial for GT products designed against particular gene mutations, as it determines suitable trial participants. When such reliable genetic diagnostic tests are not available, the desired approach would be to have companion diagnostics developed by Sponsors to ensure that subjects are properly selected.
Disease severity or its stage, as part of the benefit-risk profile, should be taken into consideration for the planning of first-in-human trials, as well. Adult subjects should be enrolled in early-phase trials wherever possible as they are able to provide informed consent and will provide early phase data on safety and tolerability. When no human safety or efficacy data exist, a proper justification should be made to conduct subsequent pediatric trials, with consideration of the ethical aspects for this vulnerable population.
Importance of Dose Selection
Early-phase studies guiding dose-ranging are critical for GT products to achieve safe and therapeutic doses. In this case, subjects may only have one shot to receive the therapy (or in some cases two), thus the choice of an initial dose is especially important. When administration of the product poses a significant risk or the subjects are pediatric, choosing an initial dose that is reasonably safe and shows some evidence of positive clinical activity, supported by the results from the preclinical studies and any existing clinical data, is necessary.
If surgical products (where invasive surgical procedures are necessary to administer the product) require FDA consideration, the FDA recommends a staged approach. Bilateral delivery in early-phase studies should be avoided because it will be difficult to know if these have achieved safety, and single side delivery can take place in a reasonable number of subjects.
Addressing Safety Concerns in Gene Therapy
The immune responses evoked against the products of GT can be a safety concern since virally delivered therapeutic transgenes can render damage to the tissues transduced. Sponsors need to include immunoassays to detect systemic immune responses and to reduce immune responses, e.g., through immunosuppressant therapies prior to and after product administration. Choice of immunosuppressant regimen should be justified based on existing clinical data for the investigational product or a related product. The risk of complications due to immunosuppressant drugs can be minimized through close observation of subjects and appropriate treatments.
Defining Study Endpoints
The FDA recommends that sponsors consider a diverse spectrum of endpoints in early-phase testing to evaluate preliminary safety, activity and efficacy of GT products. Clinical endpoints should indicate a possibility of clinical benefit, and efficacy endpoints from biomarkers and surrogate endpoints may reflect activity of the GT product. Endpoint assessments like these can inform the next steps in clinical development and optimize trial designs.
The Role of Patient Experience in Clinical Trials
Pre-marketing indication studies should have one of two types of primary efficacy endpoints: It should be a measure of a clinical benefit (meaning that your endpoint is in your patient context) or a surrogate endpoint (a biological marker who is reasonable likely to predict a clinical benefit). The nature of many neurodegenerative diseases is that they are rare and complex, making it difficult to identify and characterize surrogate or intermediate endpoints. Accordingly, an effect on a clinically meaningful endpoint is usually required to support a marketing application via the traditional approval pathway. In contrast, for the limited group of GT products which directly address a defined simplistically monogenic cause of a serious neurodegenerative disease, a mechanistically appropriate surrogate measure may be acceptable to support accelerated approval.
Weighing management of surrogate endpoints for accelerated approval, FDA expects early communication between sponsors during product development. It facilitates a complete view of the needs to be met for the use of surrogate endpoints to speed up the registration.
Follow-Up: Clinical trials vary in their duration of follow up due to vector persistence, genome integration, transgene activity, and whether the focus of follow-up is safety or the durability of clinical effect. Long-term follow up is important to assess safety and durability of clinical effects and explore the long-term impact of the product on patients.
Patient Experience: To understand the potential clinical benefit and the impact of GT products on patients’ quality of life, it is important to generate patient experience data during product development. First, the agency says it would encourage sponsors to incorporate patient experience data into marketing applications, as complementary evidence of the effects of the product on the patients’ lives.
Genetic Diagnosis and Companion Diagnostics
These seminal considerations provided by the FDA for clinical trials of gene therapy products for neurodegenerative diseases will be invaluable in optimizing trial designs, safeguarding patients, and proving efficacy. Following these guidelines will enable researchers and sponsors to deliver new neurodegenerative disorder changing therapies to patients faster, providing hope to many people suffering from such challenging diseases.
Conclusion
Discussions during the meeting, along with data and experience generated from these studies will continue to influence the future of both gene therapy and of the FDA. Considering that the gene therapy field is only in its infancy, with such future possibilities, gene therapy is a unique weapon against neurodegenerative diseases.
Today reach out to BioBoston Consulting or visit our site to learn more about how we can help your organization.
